Concepedia

Henrik Möbitz

HM

Statistics

Publications

23

Citations

1.3K

H-Index

20

Active since

2000

Affiliations

Novartis (Switzerland)(Current)

Novartis Institutes for BioMedical Research

Novartis (United States)

Novartis (China)

University of Freiburg

Henrik Möbitz is an author at Novartis (Switzerland) specializing in drug discovery, medicinal chemistry, and drug design.

ORCID

Publications per year

2000–2024

23

Publications

23

Discovery of Orally Active Inhibitors of Brahma Homolog (BRM)/SMARCA2 ATPase Activity for the Treatment of Brahma Related Gene 1 (BRG1)/SMARCA4-Mutant Cancers

Julien P. N. Papillon, Katsumasa Nakajima, Christopher D. Adair et al. · Journal of Medicinal Chemistry · 2018 · 237 citations · Full text

, , +11

Discovery of WRN inhibitor HRO761 with synthetic lethality in MSI cancers

Stéphane Ferretti, Jacques Hamon, Ruben de Kanter et al. · Nature · 2024 · 113 citations · Full text

, , +17

Optimization of a Dibenzodiazepine Hit to a Potent and Selective Allosteric PAK1 Inhibitor

Alexei S. Karpov, Payman Amiri, Cornelia Bellamacina et al. · ACS Medicinal Chemistry Letters · 2015 · 109 citations · Full text

, , +16

Type II Inhibitors Targeting CDK2

Leila T. Alexander, Henrik Möbitz, Peter Drueckes et al. · ACS Chemical Biology · 2015 · 102 citations · Full text

, , +13

Discovery of Cyclic Sulfone Hydroxyethylamines as Potent and Selective β-Site APP-Cleaving Enzyme 1 (BACE1) Inhibitors: Structure-Based Design and in Vivo Reduction of Amyloid β-Peptides

Heinrich Rueeger, Rainer Lueoend, Olivier Rogel et al. · Journal of Medicinal Chemistry · 2012 · 99 citations · Full text

, , +16

1–5 of 23